Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The FDA has granted fast track designation to TUB-040, a NaPi2b-targeted antibody-drug conjugate, for the treatment of patients with platinum-resistant ovarian…
Gilead Sciences is acquiring Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestone payments. The Munich-based biotech specializes in antibody…
Gilead Sciences completed its acquisition of Tubulis GmbH on May 21, 2026. Gilead acquired all the outstanding equity of Tubulis for $3.15 billion in upfront…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Gilead acquired German ADC specialist Tubulis for $3.15B upfront (cash-free, debt-free) plus up to $1.85B in milestones (~$5B total). The acquisition closed on May 21, 2026. It brings lead asset TUB-040 (NaPi2b TOPO1i ADC in Phase 1b/2 for platinum-resistant ovarian cancer; FDA Fast Track), TUB-030 (5T4 ADC), and a next-gen ADC platform. The Tubulis team remains in Munich as The Tubulis ADC Innovation Center, a dedicated next-gen ADC hub within Gilead.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Tubulis GmbH (this deal) | 2026 | $5.0B | — |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2026 deals · Gilead Sciences Inc. deals · Oncology deals